Review Article

Research Progress of the Functional Role of ACK1 in Breast Cancer

Xia Liu,1 Xuan Wang,2 Lifang Li,1 and Baolin Han1

1Department of Radiotherapy, Tianjin Baodi Hospital, Baodi Clinical College of Tianjin Medical University, Tianjin 301800, China
2Department of Critical Care Medicine, Tianjin Baodi Hospital, Baodi Clinical College of Tianjin Medical University, Tianjin 301800, China

Correspondence should be addressed to Baolin Han; tjhanbaolin@163.com

Received 27 May 2019; Accepted 13 September 2019; Published 20 October 2019

Abstract

ACK1 is a nonreceptor tyrosine kinase with a unique structure, which is tightly related to the biological behavior of tumors. Previous studies have demonstrated that ACK1 was involved with multiple signaling pathways of tumor progression. Its crucial role in tumor cell proliferation, apoptosis, invasion, and metastasis was tightly related to the prognosis and clinicopathology of cancer. ACK1 has a unique way of regulating cellular pathways, different from other nonreceptor tyrosine kinases. As an oncogenic kinase, recent studies have shown that ACK1 plays a critical regulatory role in the initiation and progression of tumors. In this review, we will be summarizing the structural characteristics, activation, and regulation of ACK1 in breast cancer, aiming to deeply understand the functional and mechanistic role of ACK1 and provide novel therapeutic strategies for breast cancer treatment.

1. Introduction

Breast cancer is the most common type of cancer and the leading cause of cancer-related death among women worldwide [1]. Although modern medicine for comprehensive treatment of breast cancer has improved a lot with a reduced mortality rate, however, the prevention and treatment of breast cancer remain problematic. Triple-negative breast cancer still lacks effective drug treatment today [2]. Breast cancer research found that many ACK1 tyrosine kinase signaling proteins in many tumor cells are activated repeatedly [3–6]. ACK1 expression is positively correlated with the severity of the disease progression and negatively correlated with the survival rate in breast cancer patients [7, 8].

As a nonreceptor tyrosine kinase (or cytoplasmic tyrosine kinase), ACK1 does not receive signals directly from outside the cell but is activated quickly. Its activation is tightly regulated by receptor tyrosine kinases’ activation [9–11]. The process is tightly and dynamically controlled by a series of the single signal paths or multiple phosphorylation cascades and forms tyrosine kinase connection [3, 12]. These signaling processes are dysfunctional during accelerated growth and differentiation of cells. It has been found that the overexpression of ACK1 is related to various tumors, including lung, prostate, stomach, pancreatic, breast, and ovarian cancers [8, 12–16]. Therefore, ACK1 plays a significant role in tumors, but the mechanism of activation and regulation in these tumors is not the same. This review summarizes the function and mechanism of ACK1 in breast cancer, aiming to deeply understand the relationship between ACK1 and breast cancer and providing a basis for personalized treatment of breast cancer.

2. Structure and Function of ACK1

Human ACK1 is a 120 kDa protein that contains 1038 amino acid residues [3, 17]. Its coding gene TNK2 is located in the region of chromosome 3q29 [6]. ACK1 plays a role based on its unique structural characteristics, and it contains many...
essential functions of some domains have been reported. For instance, the SAM domain was involved with the membrane localization, dimerization, and activation of ACK1 [18, 19]. The CRIB domain mediates the interaction between ACK1 and Cdc42 [3, 20], and the PPXY motif mediates the interaction between ACK1 and WW domain [21]. The MHR domain mediates the interaction between ACK1 and receptor tyrosine kinase [22]. The UBA domains are involved with the regulation of ACK1 binding to ubiquitin and its polyubiquitination and degradation [23].

3. Activation and Degradation of ACK1 in Breast Cancer Cells

ACK1 high expression is closely related to the progress of breast cancer. ACK1 kinase domain interaction with the downstream SH3, CRIB, proline-rich sequence, and MHR domain to affect its kinase activity. A pathological condition characterized by the activation of ACK1, or excessive expression, mainly with three ways of ACK1 activation [24]: (1) Just like a variety of other receptor tyrosine kinases, ACK1 goes through protein interaction and then activates itself. Cells treated with growth factors showed not only rapid activation of their respective RTK, but also activation of ACK1 through tyrosine phosphorylation [7, 25, 26]. This phenomenon suggested that multiple RTKs may potentially interact with ACK1 to cause its activation. (2) The upregulation of the ACK1 gene results in increased mRNA and protein level, which further promotes its dimerization and activation. This process serves as another activation mechanism independent of the RTK-regulated activation in many cancer types. The upregulation of ACK1 has been previously observed in various cancer types such as cervical, ovarian, lung, head and neck squamous cell, breast, prostate, and stomach cancers [6, 7, 15, 27–30]. (3) The mutation results in abnormal activation of ACK1, which can be activated by disinhibition. Among them, four missense mutations, R34L, R99Q, E346K, and M409I, were evidently reported to be located in different regions of ACK1 [5, 7]. The ACK1-E346K mutation was the first to be identified in ovarian cancer with a significant increase in ACK1 self-activation [7, 31, 32].

However, in breast cancer, ACK1 gene upregulation (3.4%) and somatic automatic activation mutation (0.1%) are relatively rare, and their activation is mainly by the interaction between RTK and ACK1 [33]. Recent studies have shown that several ubiquitination enzymes, including NEDD4-1 [21], NEDD4-2, SIAH1, and SIAH2 [34], can ubiquitinate ACK1 and induce ACK1 degradation [23, 34]. SIAH2 may be a target gene of E2/ER (estrogen receptor) and regulate the ubiquitylation and degradation of ACK1. In ER-positive breast cancer cells, the cells can activate the ER and estrogen and then ubiquitin ACK1 and reduce the ACK1 level. The lack of ER may increase the stability of ACK1, and in the absence of estrogen, breast cancer cells continually express ACK1. Therefore, it is very important to promote the survival and metastasis of breast cancer.

4. Biological Behavior of ACK1 in Breast Cancer Cells

The biological behavior of ACK1 in breast cancer cells is mainly manifested as promoting the growth and proliferation of tumor cells and promoting the metastasis and invasion of tumor cells. ACK1 is of great significance for the survival of cancer cells. ACK1 promotes cell survival by actively regulating survival pathways to prevent cell death [6]. Previous studies have found that the phosphorylation of ACK1 may be related to the progression of breast cancer [3, 7]. However, the functional signals expressed by ACK1 and their role in the biological behavior of breast cancer have not been well elucidated.

5. ACK1 Promotes the Proliferation of Breast Cancer Cells

Most mammalian cells experience cell cycle arrest, followed by apoptosis, a process that is out of control and leads to tumor development [35, 36]. Yorkie, a transcription coactivator, promotes the transcription of proliferation and antiapoptotic genes, with which ACK1 can interact to promote tissue overgrowth [37]. Besides, ACK1 S985N mutation promotes cell proliferation, migration, and epithelial-mesenchymal transition [6]. Protein kinase AKT plays a central role in the cell growth, proliferation, and cell survival; AKT activation occurs in the ligand combined with RTK and promotes AKT transport to the plasma membrane [38]. Past researches mainly focus on RTK-mediated PI3K/AKT activation, and recent studies have found that RTK/ACK1/AKT signaling pathway is independent of the path of PI3K in regulating AKT activation. Around a third of the breast cancer showed AKT abnormal activation, and ACK1 promotes cell growth and proliferation by interacting with AKT [4, 6, 39].

6. ACK1 Is Involved in the Metastasis and Invasion of Breast Cancer Cells

ACK1 can enhance the migration and invasion ability of breast cancer cells by strengthening the EGFR signaling pathway [40]. ACK1 enhances cancer-causing epidermal growth factor (EGFR) signaling and has been shown to increase proliferation and invasiveness of breast cancer cells [41, 42]. Clinically, more than 20% of breast cancer patients are diagnosed with positive human epidermal growth factor receptor (EGFR), which is associated with a reduced survival rate of breast cancer [43, 44]. The effect of ACK1 on the EGFR signaling pathway has been demonstrated to promote cell migration by activating CDC42. Jillian Howlin et al. observed that the significant decrease of EGFR on the cell surface knocked down by ACK1 was caused by the parallel reduction in the migration ability of breast cancer cells [42]. The primary role of EGFR activation in breast cancer cells is to stimulate exercise, and it has been demonstrated for the first time that maintaining the ability of EGFR cell surface expression through ACK1 can enhance the invasion ability of breast cancer cells. Meanwhile, ACK1 inhibits the
invasion of breast cancer cells by regulating BCAR1, but the mechanism remains unclear [42].

7. ACK1 Serves as a Marker for Diagnosis and Prediction of Breast Cancer

ACK1 is phosphorylated with tyrosine and interacts with many protein substrates to regulate critical cellular processes [3]. Previous studies have found that phosphorylation of ACK1 may be associated with breast cancer progression; ACK1 has specificity in phosphorylation that affects signal transmission at different sites [3, 7]. Most of its phosphorylation sites are unique, and this property is caused by the unusual substrate binding ability of ACK1 [45]. Detection of its tyrosine phosphorylation will help in the diagnosis, treatment, and prognosis of breast cancer.

The phosphorylation levels of ACK1’s Tyr284-phosphorylation and AKT’s Tyr176 phosphorylation are positively correlated with the severity of disease progression and negatively correlated with the survival rate of breast cancer patients. A significant increase in phosphorylation of ACK1-Tyr284 is a marker of ACK1 activation [7, 12, 26, 46], and this increased ACK1 activation is associated with poor tumor prognosis. In addition, the detection of p-Tyr176-AKT level in tumor biopsy can be used as an auxiliary diagnostic tool for personalized treatment with ACK1 inhibitors. ACK1 inhibitor combinations have been shown to benefit pancreatic, lung, breast, and prostate cancers that exhibit robust AKT Tyr176 phosphorylation [6, 12]. AKT phosphorylation at Ser473 phosphorylation (or thr308 phosphorylation) evaluates AKT activation and is generally evaluated as a positive outcome that can be treated with an inhibitor. PY318 phosphorylation is increased in triple-negative breast cancer cells [47]. Current studies have shown that ACK1 is not only hyperphosphorylated but also overexpressed in many highly aggressive triple-negative and triple-negative breast cancer cell lines and that ACK1 expression is associated with aggressive phenotypes in triple-negative breast cancer cell lines. AKT Tyr176 phosphorylation is abnormal in triple-negative breast cancer cell lines, which is sensitive to the ACK1 inhibitor (R-9BMS). Treating with ACK1 inhibitor (R-9BMS) can affect the proliferation of TNBCs, and through the detection of tyrosine phosphorylation will provide help for the diagnosis, treatment, and prognosis of breast cancer.

8. ACK1 and Endocrine Therapy for Breast Cancer

Breast cancer is a kind of heterogeneous disease. Endocrine therapy is an important means of comprehensive treatment of breast cancer in addition to surgery. The advantage of ER expression in breast cancer cells and the cell dependence on estrogen make tamoxifen successful in the treatment of ER-positive breast cancer, which can reduce the recurrence of breast cancer by nearly 50% [48]. Although most breast tumors initially respond well to tamoxifen therapy, most women develop tamoxifen resistance at approximately 15 months to 5 years [49]. Despite intensive research, the molecular mechanisms of tamoxifen resistance remain unclear. Drug resistance is a major clinical problem in breast cancer patients, and an in-depth understanding of this phenomenon will significantly help HER2-positive patients. Mahajan et al. demonstrated that ACK1 regulated HOXA1 expression and gave tamoxifen resistance by regulating the epigenetic activity of ER coactivator KDM3A without E2 [33]. Homeobox A1 (HOXA1) gene is a potent oncogene, and the active expression of HOXA1 is enough to cause the oncogenic transformation of human breast epithelial cells and has the ability of invasive tumor [50]. The expression of HOXA1 was significantly increased in regulatory therapy but was significantly downregulated in MCF-7 breast cancer cells treated with ACK1 inhibitor AIM-100 and dasatinib. The combined regulatory activity of ER mediated by ACK1 is crucial for promoting the transcription of HOXA1 gene. In the absence of estrogen, the regulatory protein ACK1 activates the Tyr-1114 phosphorylation site in the ER coactivator KDM3A. ER target gene transcription is promoted in estrogen-deficient environments, such as HOXA1. This may be a novel molecular mechanism for the acquisition of tamoxifen resistance in breast tumors with overexpression of HER2. This provides a new method for endocrine therapy of breast cancer patients; that is, ACK1 inhibitor AIM-100 or dasatinib inhibits ACK1 signal to alleviate the upregulation of drug resistance by HOXA1 in breast cancer patients [5]. ACK1 inhibitors have become a potential treatment for antihormone therapy of tumors in a variety of mechanisms that promote ACK1 activation in breast cancer [6]. This approach to personalized drug therapy may be beneficial for patients with tamoxifen-resistant breast cancer, revealing ACK1 inhibitor treatments such as dasatinib therapy, which is already an FDA-approved drug as an adjuvant treatment regimen.

A recent study found ACK1 regulation by AR signal is the critical mechanism; the ACK1 expression increased in quite several prostate cancer samples and ACK1 tyrosin284 phosphorylation also significantly increased, and the ACK1 activation was associated with poor prognosis of tumors. ACK1 Tyr284 phosphorylation and AR Tyr267 phosphorylation were positively correlated with the severity of the disease progression [7, 26, 52]. ACK1 phosphorylates AR and then promotes transcriptional activation at the target promoter. Activated ACK1/pTyr267-AR complex was recruited into ATM (ataxia telangiectasia mutant kinase) [46]. ATM is a regulator of DNA damage and cell cycle checkpoints signal pathway, ensuring the integrity of genes in cells to respond to DNA double-strand breaks [53]. In the absence of androgen, the Tyr267 phosphorylation of AR can promote ATM transcription, and studies have shown that increased expression of ATM protein and upregulation of genes related to maintenance of gene integrity may prevent the death of CPRC tumor cells [46]. Therefore, inhibition of ACK1-AR signaling, thereby inhibiting ACK1-mediated ATM levels, maybe a new therapeutic strategy for CRPC tumors, which often exhibits radiation resistance. The main downstream effector of ACK1 is AR, and both breast and prostate cancers are hormone-regulated cancers, indicating the potential of ER as another hormone receptor that
interacts with ACK1, possibly making breast cancer cells more sensitive to radiotherapy by inhibiting ACK1-ER signaling.

Approximately 15–20% of breast cancers do not express the estrogen receptor, progesterone receptor, or HER2 receptor, collectively known as triple-negative breast cancer (TNBC) [54]. ER-positive breast cancer or HER2 cationic breast cancer can be treated with endocrine therapy or HER2-targeted therapy [55, 56]. Compared with other types of breast cancer, these tumors are usually aggressive and lack effective targeted treatment. There is currently no targeted therapy for TNBCs patients [57, 58]. But the nonreceptor tyrosine kinase ACK1 is activated in most aggressive TNBC cell lines. Wu et al. found that inhibiting the ACK1 signal not only reduced the proliferation of TNBC cells but also promoted the invasiveness of tumor formation in xenograft mice [8]. This phenomenon indicates the dependence of TNBCs on ACK1 signal in proliferation and invasion ability. In high-level basal-like breast cancer, the high level of ACK1 expression is closely related to poor prognosis of patients [59]. It is suggested that ACK1 is a new potential therapeutic target for TNBC. The loss of ACK1 causes the death of resistant cells to the EGFR inhibitor gefitinib [33]. Therefore, combining the inhibition of EGFR and ACK1 may be a new chemotherapy strategy to overcome resistance to gefitinib [14, 60]. Combining anti-ACK1 therapy with doxorubicin therapy in the treatment of invasive TNBCs provides a pathway for future targeted therapies based on breast cancer.

9. Conclusion

To sum up, ACK1 is activated in a variety of tumors by tyrosine phosphorylation of a range of proteins, particularly those essential for cell survival, growth, and proliferation and to regulate the activity [5, 27]. To date, it has been found that ACK1 interacts with a variety of receptor tyrosine kinases (EGFR), oncoproteins (AKT), tumor suppressor proteins (Wwox), and epigenetic modification regulatory proteins (KDM3A) in breast cancer [5, 6, 11, 33, 40]. Its overactivation mainly plays a vital role in the occurrence and development of breast cancer through downstream substrates. A better understanding of ACK1 signal pathway will reveal its participation in specific cell-signaling pathways for promoting growth and inhibiting apoptosis. ACK1 inhibitor drugs will have a broad prospect of clinical application, and at the same time, ACK1 Y284 phosphorylation as a marker in some breast cancer and pTyr-1114 KDM3A antibodies also has a significant clinical diagnostic value which can be used in patients for ACK1-positive breast cancer screening. However, it is not clear whether there are other mechanisms in ACK1-related tumors to promote the growth, proliferation, migration, and invasion of cancer cells through ACK1. Moreover, more ACK1 interaction proteins or substrates need to be further identified to better utilize them for personalized diagnosis and treatment of breast cancer.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Xia Liu, Xuan Wang, and Lifang Li contributed equally to this work.

Acknowledgments

This work was supported by the grants from Health Industry Key Research Projects of Tianjin (16KG168) and Science and Technology Foundation of Tianjin Health Bureau (2012KZ003).

References

[1] L. A. Torre, F. Islami, R. I. Siegel, E. M. Ward, and A. Jemal, “Global cancer in women: burden and trends,” Cancer Epidemiology Biomarkers & Prevention, vol. 26, no. 4, pp. 444–457, 2017.
[2] H. A. Wahba and H. A. El-Hadaad, “Current approaches in treatment of triple-negative breast cancer,” Cancer Biology & Medicine, vol. 12, no. 2, pp. 106–116, 2015.
[3] K. Mahajan and N. P. Mahajan, “Shepherding AKT and androgen receptor by ACK1 tyrosine kinase,” Journal of Cellular Physiology, vol. 224, no. 2, pp. 327–333, 2010.
[4] K. Mahajan and N. P. Mahajan, “PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics,” Journal of Cellular Physiology, vol. 227, no. 9, pp. 3178–3184, 2012.
[5] K. Mahajan and N. P. Mahajan, “ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers,” Oncogene, vol. 34, no. 32, pp. 4162–4167, 2015.
[6] K. Mahajan and N. P. Mahajan, “ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation,” Cancer Letters, vol. 338, no. 2, pp. 185–192, 2013.
[7] K. Mahajan, D. Coppola, S. Challa et al., “ACK1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation,” PLoS One, vol. 5, no. 3, Article ID e9646, 2010.
[8] X. Wu, M. S. Zahari, S. Renuse et al., “The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer,” Oncotarget, vol. 8, no. 2, pp. 2971–2983, 2017.
[9] B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” Cell, vol. 129, no. 7, pp. 1261–1274, 2007.
[10] Q. Lin, J. Wang, C. Childress, and W. Yang, “The activation mechanism of ACK1 (activated Cdc42-associated tyrosine kinase 1),” Biochemical Journal, vol. 445, no. 2, pp. 255–264, 2012.
[11] V. Prieto-Echagüe and W. T. Miller, “Regulation of ack-family nonreceptor tyrosine kinases,” Journal of Signal Transduction, vol. 2011, Article ID 742372, 9 pages, 2011.
[12] K. Mahajan, D. Coppola, Y. A. Chen et al., “ACK1 tyrosine kinase activation correlates with pancreatic cancer progression,” The American Journal of Pathology, vol. 180, no. 4, pp. 1386–1393, 2012.
[13] F. Hu, H. Liu, X. Xie, J. Mei, and M. Wang, “Activated cdc42-associated kinase is up-regulated in non-small-cell lung cancer and necessary for FGFR-mediated AKT activation,” Molecular Carcinogenesis, vol. 55, no. 5, pp. 853–863, 2016.
[14] K. Mahajan, P. Malla, H. R. Lawrence et al., “ACK1/TNK2 regulates histone H4 tyrosine-phosphorylation and AR gene expression in castration-resistant prostate cancer,” Cancer Cell, vol. 31, no. 6, pp. 790.e8–803.e8, 2017.

[15] S.-H. Xu, J.-Z. Huang, M.-L. Xu et al., “ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling,” The Journal of Pathology, vol. 236, no. 2, pp. 175–185, 2015.

[16] X. Zhao, C. Lv, S. Chen, and F. Zhi, “A role for the non-receptor tyrosine kinase ACK1 in TNF-alpha-mediated apoptosis and proliferation in human intestinal epithelial cac-2 cells,” Cell Biology International, vol. 42, no. 9, pp. 1097–1105, 2018.

[17] N. Yokoyama and W. T. Miller, “Purification and enzyme activity of ACK1,” Methods in Enzymology, vol. 406, pp. 250–260, 2006.

[18] V. Prieto-Echagüe, A. Gucca, D. A. Brown, and W. Miller, “Regulation of ACK1 localization and activity by the amino-terminal SAM domain,” BMC Biochemistry, vol. 11, no. 1, p. 42, 2010.

[19] Y. R. Thaker, A. Recino, M. Raab et al., “Activated Cdc42-associated kinase 1 (ACK1) binds the sterile α motif (SAM) domain of the adaptor SLP-76 and phosphorylates proximal tyrosines,” Journal of Biological Chemistry, vol. 292, no. 15, pp. 6281–6290, 2017.

[20] N. Yokoyama and W. T. Miller, “Biochemical properties of the cdc42-associated tyrosine kinase ACK1. Substrate specificity, autophosphorylation, and interaction with Hck,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 47713–47723, 2003.

[21] Q. Lin, J. Wang, C. Childress, M. Sudol, D. J. Carey, and W. Yang, “HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK,” Molecular and Cellular Biology, vol. 30, no. 6, pp. 1541–1554, 2010.

[22] L. Pao-Chun, P. M. Chan, W. Chan, and E. Manser, “Cyttoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling,” Journal of Biological Chemistry, vol. 284, no. 50, pp. 34954–34963, 2009.

[23] W. Chan, R. Tian, Y.-F. Lee, S. T. Sit, L. Lim, and E. Manser, “Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2,” Journal of Biological Chemistry, vol. 284, no. 12, pp. 8185–8194, 2009.

[24] K. S. Gajiwala, K. Maegley, R. Ferre, Y.-A. He, and X. Yu, “ACK1: activation and regulation by allosteroy,” PLoS One, vol. 8, no. 1, Article ID e53994, 2013.

[25] N. P. Mahajan, Y. E. Whang, J. L. Mohler, and H. S. Earp, “Activated tyrosine kinase ACK1 promotes prostate tumorigenesis: role of ACK1 in polyubiquitination of tumor suppressor Wwox,” Cancer Research, vol. 65, no. 22, pp. 10514–10523, 2005.

[26] N. P. Mahajan, Y. Liu, S. Majumder et al., “Activated Cdc42-associated kinase ACK1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation,” Proceedings of the National Academy of Sciences, vol. 104, no. 20, pp. 8438–8443, 2007.

[27] B. Xie, Q. Zen, X. Wang et al., “ACK1 promotes hepatocellular carcinoma progression via downregulating Wwox and activating Akt signaling,” International Journal of Oncology, vol. 46, no. 5, pp. 2057–2066, 2015.

[28] D. S. Tan, B. Haaland, J. Gan et al., “Bosutinib inhibits migration and invasion via ACK1 in kras mutant non-small cell lung cancer,” Molecular Cancer, vol. 13, no. 1, p. 13, 2014.

[29] L. C. Kelley and S. A. Weed, “Cortactin is a substrate of activated Cdc42-associated kinase 1 (ACK1) during ligand-induced epidermal growth factor receptor downregulation,” PLoS One, vol. 7, no. 8, Article ID e4363, 2012.

[30] B. Furlow, “Tyrosine kinase ACK1 promotes prostate tumorigenesis,” The Lancet Oncology, vol. 7, no. 1, p. 17, 2006.

[31] V. Prieto-Echagüe, A. Gucca, B. P. Craddock, D. A. Brown, and W. T. Miller, “Cancer-associated mutations activate the nonreceptor tyrosine kinase ACK1,” Journal of Biological Chemistry, vol. 285, no. 14, pp. 10605–10615, 2010.

[32] J. E. Maxson, M. L. Abel, J. Wang et al., “Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis,” Cancer Research, vol. 76, no. 1, pp. 127–138, 2016.

[33] K. Mahajan, H. R. Lawrence, N. J. Lawrence, and N. P. Mahajan, “ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1,” Journal of Biological Chemistry, vol. 289, no. 41, pp. 28179–28191, 2014.

[34] M. Buchwald, K. Petschmann, P. Brand et al., “SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitylation and proteasomal degradation,” Oncogene, vol. 32, no. 41, pp. 4913–4920, 2013.

[35] R. Gerl and D. L. Vaux, “Apoptosis in the development and treatment of cancer,” Carcinogenesis, vol. 26, no. 2, pp. 263–270, 2005.

[36] S. Elmore, “Apoptosis: a review of programmed cell death,” Toxicologic Pathology, vol. 35, no. 4, pp. 495–516, 2007.

[37] J. A. Schoenherr, J. M. Drennan, J. S. Martinez et al., “Drosophila activated Cdc42 kinase has an anti-apoptotic function,” PLoS Genetics, vol. 8, no. 5, Article ID e1002725, 2012.

[38] T. F. Franke, S.-I. Yang, T. O. Chan et al., “The protein kinase encoded by the Akt proto-oncogene is a target of the PDGFR-activated phosphatidylinositol 3-kinase,” Cell, vol. 81, no. 5, pp. 727–736, 1995.

[39] J. Zhang, T. Chen, Q. Mao et al., “PDGFR-β-activated ACK1-AKT signaling promotes glioma tumorigenesis,” International Journal of Cancer, vol. 136, no. 8, pp. 1769–1780, 2015.

[40] F. Shen, Q. Lin, Y. Gu, C. Childress, and W. Yang, “Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation,” Molecular Biology of the Cell, vol. 18, no. 3, pp. 732–742, 2007.

[41] B. T. Chua, S. J. Lim, S. C. Tan, W. J. Poh, and A. Ullrich, “Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells,” Molecular Oncology, vol. 4, no. 4, pp. 323–334, 2010.

[42] J. Howlin, J. Rosenkvist, and T. Andersson, “TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells,” Breast Cancer Research, vol. 10, no. 2, 2008.

[43] A. R. Silva, “Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation,” International Journal of Surgical Pathology, vol. 14, no. 3, pp. 268–276, 2006.

[44] J. Mendelsohn and J. Baselga, “Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2787–2799, 2003.

[45] J. C. Lougheed, R.-H. Chen, P. Mak, and T. J. Stout, “Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1,” Journal of Biological Chemistry, vol. 279, no. 42, pp. 44039–44045, 2004.
[46] K. Mahajan, D. Coppola, B. Rawal et al., “ACK1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer,” *Journal of Biological Chemistry*, vol. 287, no. 26, pp. 22112–22122, 2012.

[47] X. Wu, M. S. Zahari, B. Ma et al., “Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways,” *Oncotarget*, vol. 6, no. 30, pp. 29143–29160, 2015.

[48] B. Fisher, J. P. Costantino, D. L. Wickerham et al., “Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study,” *JNCI: Journal of the National Cancer Institute*, vol. 97, no. 22, pp. 1652–1662, 2005.

[49] R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar, “Cellular and molecular pharmacology of antiestrogen action and resistance,” *Pharmacological Reviews*, vol. 53, no. 1, pp. 25–71, 2001.

[50] X. Zhang, T. Zhu, Y. Chen, H. C. Mertani, K.-O. Lee, and P. E. Lobie, “Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene,” *Journal of Biological Chemistry*, vol. 278, no. 9, pp. 7580–7590, 2003.

[51] B. S. Taylor, N. Schultz, H. Hieronymus et al., “Integrative genomic profiling of human prostate cancer,” *Cancer Cell*, vol. 18, no. 1, pp. 11–22, 2010.

[52] K. Mahajan, S. Challa, D. Coppola et al., “Effect of ACK1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity,” *The Prostate*, vol. 70, no. 12, pp. 1274–1285, 2010.

[53] Y. Shiloh, “ATM and related protein kinases: safeguarding genome integrity,” *Nature Reviews Cancer*, vol. 3, no. 3, pp. 155–168, 2003.

[54] A. Diana, E. Franzese, S. Centonze et al., “Triple-negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs,” *Current Oncology Reports*, vol. 20, no. 10, p. 76, 2018.

[55] D. R. Cochrane, D. M. Cittelly, E. N. Howe et al., “MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer,” *Hormones and Cancer*, vol. 1, no. 6, pp. 306–319, 2010.

[56] J. D. Brenton, L. A. Carey, A. A. Ahmed, and C. Caldas, “Molecular classification and molecular forecasting of breast cancer: ready for clinical application?,” *Journal of Clinical Oncology*, vol. 23, no. 29, pp. 7350–7360, 2005.

[57] J. H. Park, J. H. Ahn, and S. B. Kim, “How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies,” *ESMO Open*, vol. 3, no. 1, Article ID e000357, 2018.

[58] A. M. Ali, J. A. K. Ansari, N. M. A. El-Aziz et al., “Triple negative breast cancer: a tale of two decades,” *Anti-Cancer Agents in Medicinal Chemistry*, vol. 17, no. 4, pp. 491–499, 2017.

[59] Y. Zhang, J. Li, X. N. Lai, X.-Q. Jiao, J.-P. Xiong, and L.-X. Xiong, “Focus on Cdc42 in breast cancer: new insights, target therapy development and non-coding RNAs,” *Cells*, vol. 8, no. 2, 2019.

[60] H. R. Lawrence, K. Mahajan, Y. Luo et al., “Development of novel ACK1/TNK2 inhibitors using a fragment-based approach,” *Journal of Medicinal Chemistry*, vol. 58, no. 6, pp. 2746–2763, 2015.